

PAIN MANAGEMENT: INDIVIDUALIZED PATIENT CARE VIA COMPOUNDED ADJUNCTIVE THERAPIES

BRETT DINES, RPH MBA

DISCLOSURE OF CONFLICTS

THE PRESENTER HAS EQUITY OWNERSHIP IN APEX COMPOUNDING PHARMACY. THE PRESENTER HAS OBTAINED ACCESS TO THE CITED CLINICAL RESEARCH AND JOURNAL REFERENCES THROUGH HIS FACULTY POSITION AT THE UNIVERSITY OF COLORADO SKAGGS SCHOOL OF PHARMACY AND PHARMACEUTICAL SCIENCES. THE PRESENTERS VIEWS AND OR CLINICAL INTERPRETATION OF THE REFERENCE MATERIAL ARE NOT MEANT TO BE REPRESENTATIVE OF THOSE OF THE UNIVERSITY. THE PRESENTATION HAS BEEN REVIEWED AND APPROVED BY THE SOCIETY OF NURSES IN ADVANCED PRACTICE (SNAP) AND DETERMINED TO BE IN ACCORDANCE WITH ITS POLICY ON OBJECTIVITY IN PROVIDING CONTINUING EDUCATION.



- INTRODUCTION
- WHAT IS COMPOUNDING / REGULATORY CONSIDERATIONS
- CLINICAL RATIONALE
- ROUTE OF DELIVERY
- CLINICAL USE CASES AND REFERENCE FORMULATIONS
- CLINICAL CONSIDERATIONS

EVOLUTION OF COMPOUNDING

- APOTHECARY: HOMEOPATHIC AND TAILORED MEDICATIONS
- FD&C: DRUG EFFICACY AMENDMENT PL 87-781 (OCTOBER 10, 1962)
- ADVENT OF MANUFACTURING: RPH ROLE CHANGES FROM PREPARING TO DISPENSING
- ECONOMICS CHANGE: EVOLUTION AND COMMODITIZATION

WHAT IS COMPOUNDING?

PERSONALIZED MEDICINES

- ALLERGIES
- DOSING
- SENSITIVITIES, AVERSION TO ORAL MEDS
- RACE AND ETHNICITY GENETIC EFFECTS: METABOLISM, DISTRIBUTION, ELIMINATION¹
- SIDE EFFECTS, COMORBIDITIES, DRUG DRUG

1) Balmaceda CM, The impact of ethnicity and cardiovascular risk on the pharmacologic management of osteoarthritis: a US perspective. Postgrad Med January 2015, Vol. 127, No. 1, Pages 51-56

REGULATORY CONSIDERATIONS

- NOT A FDA 505(B)1, 505(B)2, OR 505(J)
- NOT A COMMERCIAL COPY
- NOT ON FDA BANNED SUBSTANCE LIST
- 503(A) AND 503(B) EXEMPTED FROM NDA AND LISTED AS A LEGEND DRUG ²
- DOES REQUIRE A PRESCRIPTION

2) US FDA: Compounding Quality Act http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/P harmacyCompounding/ucm375804.htm Accessed 03/15/2015

CLINICAL RATIONALE

 DEVELOPED TO ALIGN WITH RECOMMENDATIONS FROM FDA AND SEVERAL PROFESSIONAL MEDICAL ORGANIZATIONS THAT NSAIDS BE USED AT THE LOWEST EFFECTIVE DOSE FOR THE SHORTEST POSSIBLE DURATION CONSISTENT WITH INDIVIDUAL PATIENT TREATMENT GOALS¹

¹U.S. Food and Drug Administration. Public Health Advisory – FDA Announces Important Changes and Additional Warnings for COX-2 Selective and Non-Selective Non-Steroidal Anti-Inflammatory Drugs (NSAIDs).

ROUTE OF ADMINISTRATION AND DISTRIBUTION MULTI COMPARTMENT MODELING

<u>ORAL</u>

TRANSDERMAL OR TOPICAL^{1,2}

- GI: WEAK ACIDS, COX1
- LIVER FIRST PASS
- HIGH PLASMA > LOW TISSUE
- INFLAMMATION IMPACTS INFILTRATION
- T(MAX) ~2.5 BIOLOGICAL HALF LIVES

1) Kienzler JL. Et al Systemic Bioavailability of topical diclofenac sodium gel 1% versus oral diclofenac sodium in healthy volunteers J Clin Pharmacology 2010;50:50-61 PENETRATE THE SKIN
 ~0.55% OF IBU THROUGH STRATUM CORNEUM

- FLUX/ABSORPTION IMPACTED BY BASE
- LOCALIZED EFFECT: HIGH TISSUE > LOW PLASMA
- FASTER TIME TO T(MAX) < 1 BIOLOGICAL HALF LIFE

2) Sekiya I et al. Ketoprofen Absorption by Muscle and Tendon after Topical or Oral Administration in Patients Undergoing Anterior Cruciate Ligament Reconstruction AAPS PharmSciTech, Vol. 11, No. 1, March 2010

KINETICS, PEAK PLASMA, AUC(MAX)




DICLOFENAC PHARMACOKINETICS

Table III Summary of Day 7 Plasma Pharmacokinetic Parameters


Treatment	Cmax, ng/mL	t _{max} , h	AUC _{nas} , ng-h/mL	C _{sin} , ng/mL	Cast ng/mL	PTF, %
A (n = 39)	15.0 ± 7.33	14 (0-24)	233 ± 128	5.92 ± 3.65	9.70 ± 5.32	95.6 ± 40
B (n = 39)	53.8 ± 32.0	10 (0-24)	807 ± 478	19.2 ± 12.1	33.6 ± 19.9	106 ± 51
C (n = 39)	2270 ± 778	6.5 (1-14)	3890 ± 1710	5.70 ± 3.11	162 ± 71.2	1516 ± 61

plasma concontration; C_{max} maximum plasma concontration; G_{max} minimum plasma concontration; PTF; peak-trough fluctuation; t_{max} time to C_{max} Troutenet A = diclotions column topical gol 1% on 1 knee; treatment B = dicloting; output topical gol 1% on 2 knees and 2 hands; treatment G = diclotions; column topical gol 1% on 2 knees and 2 hands; treatment G = diclotions; column topical gol 1% on 2 knees and 2 hands; treatment G = diclotions; column topical gol 1% on 2 knees and 2 hands; treatment G = diclotions; column topical gol 1% on 2 knees and 2 hands; treatment G = diclotions; column topical gol 1% on 2 knees and 2 hands; treatment G = diclotions; column topical gol 1% on 2 knees and 2 hands; treatment G = diclotions; column topical gol 1% on 3 knees; treatment G = diclotions; column topical gol 1% on 3 knees; treatment G = diclotions; column topical gol 1% on 3 knees; treatment G = diclotions; column topical gol 1% on 3 knees; treatment G = diclotions; column topical gol 1% on 3 knees; treatment G = diclotions; column topical gol 1% on 3 knees; treatment G = diclotions; column topical gol 1% on 3 knees; treatment G = diclotions; column topical gol 1% on 4 knees; treatment G = diclotions; column topical gol 1% on 3 knees; treatment G = diclotions; column topical gol 1% on 3 knees; treatment G = diclotions; column topical gol 1% on 3 knees; treatment G = diclotions; column topical gol 1% on 3 knees; treatment G = diclotions; column topical gol 1% on 3 knees; treatment G = diclotions; column topical gol 1% on 3 knees; treatment G = diclotions; column topical gol 1% on 3 knees; treatment G = diclotions; column topical gol 1% on 3 knees; treatment G = diclotions; column topical gol 1% on 3 knees; treatment G = diclotions; column topical gol 1% on 3 knees; treatment G = diclotions; column topical gol 1% on 3 knees; treatment G = diclotions; column topical gol 1% on 3 knees; treatment G = diclotions; column topical gol 1% on 3 knees; treatment G = diclotions; column topical gol 1% on 3 knees; trea



1) Kienzler JL. Et al Systemic Bioavailability of topical diclofenac sodium gel 1% versus oral diclofenac sodium in healthy volunteers J Clin Pharmacology 2010;50:50-61


KETOPROFEN²



2) Oxford Press: Bandolier Evidence based thinking about healthcare Topical NSAIDs: penetrating the skin

CLINICAL SUCCESS WITH TOPICAL NSAIDS

Clinical success (%) with topical NSAID




Design: Review of randomized, double blinded controlled trails on efficacy and safety Size: 47 clinical studies, > 10 patients each. Clinical Success: Defined as a 50% reduction in pain or equivalent measure ... measured on a categorical scale.

Massey T et al. Topical NSAIDs for acute pain in adults (Review) The Cochrane Collaboration® 2010, Issue 6

CLINICAL RATIONALE







Log [IC₈₀ ratio (William Harvey Human Modified Whole Blood Assay (WHMA) COX-2/COX-1)]

Kerr S, et al. National Prescribing Service Cox-Selective Nsaids: New wonder Drugs ACN 082 034 393


PHARMACOLOGY FIXED DOSE COMBINATION COMPOUNDS



FIXED DOSE COMBINATION COMPOUNDS



FIXED DOSE COMBINATION COMPOUNDS



O'Brien J et al. Fixed-dose combinations at the front line of multimodal pain management: perspective of the nurse-prescriber Nursing: Research and Reviews 2013:3 9–22

PHARMACOLOGY AND COMPOUND FORMULA DRIVEN BY ETIOLOGY



Anti-Inflammatory creams joints & muscles

Diclofenac 5%, Baclofen 2%, Cyclobenzaprine 2%, Bupivacaine 1%
Diclofenac 5%, Cyclobenzaprine 2%, Tramadol 10%

Neuropathic pain creams



 Gabapentine 6%, Cyclobenzaprine 2%, Tramadol 10%, Lidocaine 5%, Ketamine 10%
 Gabapentin 6%, Clonidine 0.2%, Imipramine 3% Lidoca

• Gabapentin 6%, Cionidine 0.2%, Imipramine 3%,Lidocaine 5%, Ketamine 10%

• Gabapentin 6%, Carbamazepine 2%, Tramadol 10%, Ketamine 10%




<u>Neuropathic & anti-inflammatory combo</u>

<u>creams</u>

• Diclofenac 5%, Gabapentin 6%, Baclofen 2%, Cyclobenzaprine 2%, Bupivacaine 1%, Ketamine 10% CONSIDERATIONS WITH COMPOUNDED MEDICATIONS CONTRAINDICATIONS AND SIDE EFFECTS

- ANYTHING YOU WOULD
 MONITOR WITH AN ORALLY
 ADMINISTERED PRODUCT
- NORMAL SIDE EFFECTS
 DIMINISHED, BUT NOT LOST



- RENAL INSUFFICIENCY
- DRUG-DRUG INTERACTIONS
- HYPERTENSION: K AND NSAIDS
- NO FLY LIST FOR PILOTS
- COST

QUIZ

QUESTIONS

- 1) COMPOUNDS MUST COMPLETE THE NEW DRUG APPROVAL PROCESS TO ACHIEVE MARKETING AUTHORIZATION IN THE USA?
- 2) TOPICAL COMPOUNDS CAN NOT ACHIEVE THE SAME PLASMA CONCENTRATIONS AS ORALLY?
- 3) TOPICAL DELIVERY CAN RESULT IN A FASTER TIME TO T(MAX) AT THE SITE OF INJURY VS THE ORAL ROUTE OF DELIVERY?

4) FIXED DOSE COMBINATION PRODUCTS USED ADJUNCTIVELY CAN IMPACT OPIATE UTILIZATION?

5) TOPICAL NSAIDS CAN BE USED IN PATIENTS ON PERITONEAL DIALYSIS?

EXAMPLES AND DOSING OF MEDICATIONS USED IN TRANSDERMAL DELIVERY

Drug	Strength	Mechanism
Amitriptyline	1-5%	NE Reuptake inhibitor
Baclofen	2-5%	$GABA_{\beta}$ Agonist
Bretylium	1-5%	Sympathetic Inhibition
Bupivicaine	0.25-10%	Anesthetic
Capsaicin	0.025-0.1%	Substance P Blockade
Carbamazepine	2-5%	NMDA Na ⁺ Blocker
Clonidine	0.1-0.3%	Alpha -2 Agonist
Cyclobenzaprine	1-4%	Muscle Relaxant
Dextromethorphan	5-10%	NMDA Receptor Antagonist

EXAMPLES AND DOSING OF MEDICATIONS USED IN TRANSDERMAL DELIVERY

Drug	Strength	Mechanism
Diclofenac	2-10%	Cyclooxygenase Inhibitor
Diphenhydramine	5-10%	Voltage Regulated Na ⁺ & Ca ⁺⁺ Blockade
Gabapentin	5-10%	Voltage Regulated Na ⁺ & Ca ⁺⁺ Blockade Glutamate Antagonist
Guaifenesin	5-10%	Muscle Relaxant
Ibuprofen	10-30%	Propionic Acid NSAID
Indomethacin	15-20%	Methylated Indole NSAID
Lidocaine	2-10%	Anesthetic
Lipoic Acid	2-3%	Antioxidant
Loperamide	5-10%	Mu agonist

EXAMPLES AND DOSING OF MEDICATIONS USED IN TRANSDERMAL DELIVERY

Drug	Strength	Mechanism
Naproxen	10-20%	Propionic Acid NSAID
Nifedipine	0.2-16%	Non-NMDA Ca ⁺² Channel Antagonist
Pentoxifylline	5-15%	TNF_{α} Inhibitor, Peripheral Vasodilator
Phenytoin	0.5-2%	NMDA Na ⁺ Blocker